Low Thyroid Symptoms: Drugs That Cause or Treat Hypothyroidism

Why Hypothyroid Symptoms Happen

Thyroid hormones regulate basal metabolic rate, thermogenesis, heart rate, gut motility, and cognitive tempo. When circulating free T4 and free T3 drop below the body's set point, every organ system slows. Fatigue appears first. Weight gain, constipation, cold intolerance, dry skin, and brain fog follow within weeks to months.

The hypothalamic-pituitary-thyroid axis compensates by raising TSH, which is why an elevated TSH is the earliest and most sensitive laboratory marker of primary hypothyroidism [1]. A TSH above 10 mIU/L with a low free T4 confirms overt disease. Subclinical hypothyroidism, defined as TSH between 4.5 and 10 mIU/L with a normal free T4, affects an additional 4% to 8% of the general population and can still produce noticeable symptoms in some individuals [2]. The distinction matters because treatment thresholds differ. The American Thyroid Association (ATA) recommends treatment for all patients with TSH above 10 mIU/L and individualized decisions for subclinical cases based on age, symptoms, cardiovascular risk, and anti-TPO antibody status [3].

Drugs That Cause Hypothyroid Symptoms

At least a dozen widely prescribed medications interfere with thyroid function through distinct mechanisms. Recognizing drug-induced hypothyroidism prevents unnecessary lifelong thyroid replacement when stopping the offending agent could resolve symptoms.

Lithium remains the most well-documented thyroid-suppressing drug. It concentrates in the thyroid gland at 3 to 4 times the plasma level, inhibiting iodine organification and thyroid hormone release. A meta-analysis of 13 studies found that lithium users had a 5.78-fold increased risk of hypothyroidism compared with controls (OR 5.78 to 95% CI 2.00 to 16.67) [4]. Between 20% and 40% of patients on long-term lithium develop elevated TSH. The Endocrine Society recommends checking TSH before starting lithium and every 6 to 12 months thereafter [5].

Amiodarone contains 37% iodine by weight. Each 200 mg tablet delivers roughly 75 mg of organic iodine, about 50 times the recommended daily intake. This iodine load triggers the Wolff-Chaikoff effect, blocking thyroid hormone synthesis. Amiodarone-induced hypothyroidism (AIH) occurs in 5% to 25% of treated patients, with higher rates in iodine-sufficient populations [6]. It also inhibits peripheral T4-to-T3 conversion through type 1 deiodinase blockade. Patients on amiodarone require TSH monitoring every 3 to 6 months for the duration of therapy and for up to 12 months after discontinuation, given the drug's 40- to 55-day half-life.

Immune checkpoint inhibitors (nivolumab, pembrolizumab, ipilimumab) cause thyroid dysfunction in 5% to 20% of treated cancer patients [7]. The mechanism involves immune-mediated thyroiditis, which can present as transient thyrotoxicosis followed by permanent hypothyroidism. Anti-PD-1 agents carry a higher thyroid toxicity rate than anti-CTLA-4 agents. Combination immunotherapy raises the incidence further. The 2022 ASCO guideline recommends TSH and free T4 at baseline, before each cycle for the first 6 months, then every 3 months [8].

Tyrosine kinase inhibitors (sunitinib, sorafenib, imatinib) induce hypothyroidism in 20% to 50% of patients, likely through destructive thyroiditis and reduced thyroid vascularity [9]. Sunitinib has the strongest association.

Other offenders include interferon-alpha (used in hepatitis C therapy, 5% to 15% incidence), bexarotene (used in cutaneous T-cell lymphoma, increases TSH clearance), and high-dose iodinated contrast agents in susceptible patients.

Medications That Treat Hypothyroidism

Levothyroxine: The Standard of Care

Levothyroxine (synthetic T4) is the most prescribed medication in the United States. It works. The 2014 ATA Guidelines for Treatment of Hypothyroidism recommend levothyroxine monotherapy as the standard treatment for primary hypothyroidism [3]. The drug provides a stable pool of T4 that peripheral deiodinases convert to the active hormone T3 on a tissue-by-tissue basis.

Full replacement dosing is 1.6 mcg/kg/day for most adults. A 70 kg patient needs roughly 112 mcg daily. Older adults and patients with coronary artery disease start lower, typically at 25 to 50 mcg/day, with titration every 6 to 8 weeks. The goal is a TSH within the reference range (0.5 to 4.5 mIU/L), though many clinicians target the lower half (0.5 to 2.5 mIU/L) for symptom optimization [10].

Absorption matters enormously. Levothyroxine should be taken on an empty stomach, 30 to 60 minutes before breakfast or at bedtime (at least 3 hours after eating). Calcium supplements, iron supplements, proton pump inhibitors, and coffee all reduce absorption by 20% to 40% [11]. Switching between manufacturers can shift bioavailability by 12% to 15%, which is enough to move TSH out of range. The ATA recommends maintaining the same formulation whenever possible.

Brand names include Synthroid, Levoxyl, Tirosint, and Unithroid. Tirosint is a gelcap formulation that avoids the excipients found in tablet forms and may offer more consistent absorption in patients with GI disorders or those taking concurrent medications [12].

Liothyronine (Synthetic T3)

Liothyronine (Cytomel) delivers T3 directly. Its half-life is short, approximately 1 day, compared with levothyroxine's 7-day half-life. This creates peak-and-trough fluctuations in serum T3 that can cause palpitations, anxiety, and insomnia at peak levels.

Some patients report persistent fatigue, brain fog, and mood disturbance despite a normal TSH on levothyroxine alone. The hypothesis is that impaired peripheral T4-to-T3 conversion, potentially linked to polymorphisms in the DIO2 gene (Thr92Ala variant), leaves certain tissues T3-deficient even when serum levels appear adequate [13]. A 2009 study in the Journal of Clinical Endocrinology and Metabolism found that DIO2 Thr92Ala carriers showed improved well-being on combination T4/T3 therapy compared with T4 monotherapy [14].

The 2014 ATA Guidelines state that combination therapy "could be considered as an experimental approach" in patients with persistent symptoms despite biochemical euthyroidism on levothyroxine alone [3]. They recommend a T4:T3 ratio of 13:1 to 20:1, approximating physiologic thyroid secretion. A practical regimen: reduce levothyroxine by 25 mcg and add 5 mcg of liothyronine twice daily.

Desiccated Thyroid Extract

Natural desiccated thyroid (NDT), sold as Armour Thyroid and NP Thyroid, is derived from porcine thyroid glands. It contains both T4 and T3 in a fixed ratio of approximately 4.2:1, which delivers proportionally more T3 than the human thyroid produces (14:1 ratio). A randomized crossover trial of 70 patients published in JCEM found no difference in symptoms, neurocognitive function, or quality of life between NDT and levothyroxine, though 49% of participants preferred NDT [15].

NDT has drawbacks. Batch-to-batch potency varies slightly. The supraphysiologic T3 content can suppress TSH below the reference range, raising concerns about atrial fibrillation and bone loss, particularly in postmenopausal women [16]. The ATA does not recommend NDT as first-line therapy but acknowledges that it may be "an alternative" for patients who feel inadequately treated on levothyroxine.

Drugs That Interfere with Thyroid Replacement

Starting levothyroxine does not end the medication complexity. Several drug classes alter thyroid hormone absorption, binding, or metabolism, requiring dose adjustments.

Absorption blockers. Calcium carbonate, ferrous sulfate, aluminum hydroxide antacids, sucralfate, cholestyramine, and sevelamer all bind levothyroxine in the gut. A 2010 study showed that calcium carbonate taken concurrently with levothyroxine raised TSH by an average of 1.76 mIU/L within 2 months [11]. The fix is straightforward: separate dosing by at least 4 hours.

Proton pump inhibitors. Omeprazole and other PPIs reduce gastric acid, impairing dissolution of levothyroxine tablets. Patients on long-term PPIs may need a 20% to 30% dose increase [17]. Liquid or gelcap formulations (Tirosint) bypass this issue.

Estrogen. Oral estrogen therapy increases thyroxine-binding globulin (TBG) by 20% to 50%, reducing free T4 levels. Women starting oral contraceptives or menopausal hormone therapy on levothyroxine often need a dose increase of 25 to 50 mcg [18]. Transdermal estrogen avoids first-pass hepatic effects and does not significantly alter TBG.

Enzyme inducers. Phenytoin, carbamazepine, rifampin, and phenobarbital induce hepatic cytochrome P450 enzymes that accelerate T4 clearance. TSH should be rechecked 6 to 8 weeks after starting or stopping any of these drugs.

Monitoring and Dose Optimization

The goal of thyroid replacement is not a number on a lab report. It is resolution of symptoms. TSH is the primary monitoring parameter, checked every 6 to 8 weeks after any dose change and annually once stable [3]. Free T4 and free T3 add value when TSH is discordant with clinical presentation, for example a normal TSH in a patient who remains symptomatic.

A 2018 study in Thyroid analyzed data from 5,401 hypothyroid patients and found that 15.6% reported persistent symptoms despite TSH normalization on levothyroxine [19]. Possible explanations include autoimmune comorbidities (vitamin B12 deficiency, celiac disease, adrenal insufficiency), sleep disorders, and the psychosocial burden of chronic disease.

Dr. Antonio Bianco, a professor of medicine at the University of Chicago and a leading researcher in thyroid hormone metabolism, has written: "The current standard of care with levothyroxine monotherapy does not restore euthyroidism in all tissues of all patients. We need to identify who these patients are and offer them individualized solutions" [20].

Before attributing persistent symptoms to thyroid undertreatment, clinicians should screen for iron deficiency (ferritin <30 ng/mL), vitamin D insufficiency (<30 ng/mL), vitamin B12 deficiency, and obstructive sleep apnea. Each of these conditions mimics hypothyroid symptoms and is independently common.

Special Populations

Pregnancy. Thyroid hormone requirements increase by 25% to 50% during pregnancy, beginning as early as the first trimester. The 2017 ATA pregnancy guidelines recommend a TSH target of <2.5 mIU/L in the first trimester and trimester-specific reference ranges thereafter [21]. Inadequately treated maternal hypothyroidism is associated with preeclampsia, placental abruption, and impaired neurocognitive development in offspring.

Elderly patients. In adults over 70, a TSH of 4.5 to 7.0 mIU/L may be age-appropriate and does not require treatment. The TRUST trial (N=737, mean age 74) randomized older adults with subclinical hypothyroidism (TSH 4.6 to 19.9 mIU/L) to levothyroxine versus placebo and found no improvement in thyroid-related symptoms or fatigue at 12 months [22]. Overtreating elderly patients risks atrial fibrillation and accelerated bone loss.

Myxedema coma. This rare, life-threatening presentation of severe hypothyroidism requires intravenous levothyroxine (200 to 400 mcg loading dose) plus IV liothyronine (5 to 20 mcg), alongside IV hydrocortisone pending adrenal assessment [23]. Mortality exceeds 30% even with aggressive treatment. This is an ICU-level emergency.

When to Suspect a Drug Is Causing Your Symptoms

A straightforward clinical clue: if hypothyroid symptoms appeared within 1 to 6 months of starting a new medication, the drug should be considered a possible cause. The timeline matters. Autoimmune thyroiditis develops over months to years. Drug-induced thyroid suppression typically produces measurable TSH elevation within 4 to 12 weeks of drug initiation.

Clinicians should check TSH and free T4 at baseline before starting any drug known to affect thyroid function. If hypothyroidism develops, the decision to treat with levothyroxine versus discontinuing the offending agent depends on whether the causative medication is medically necessary. A patient on lithium for bipolar disorder typically continues lithium and adds levothyroxine. A patient who developed hypothyroidism from a short course of amiodarone may recover thyroid function spontaneously after the drug is cleared, though this can take 6 to 9 months given amiodarone's prolonged tissue half-life.

Check TSH 6 to 8 weeks after stopping any thyroid-toxic medication to confirm recovery before concluding that replacement therapy is permanent.